leisure time -WSS

leisure time

author：fashion 2025-09-27 10:01:18 - browse：4

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The system is set up to fail children with medical complexity

Wikipedia

entertainment

WSS

New documents shed light on MD Anderson Cancer Institute feud

A solution to the after

'Essentially witchcraft:' A former naturopath takes on the field

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Lilly's Alzheimer's drug donanemab backed by FDA advisers

PBM reform efforts get punted in Congress

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

ALS patient reclaims some autonomy thanks to wearable 'robot'

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Activists slam private health insurers over coverage restrictions

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Bright Health sells Medicare Advantage business to Molina

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

focus

Coercive sterilizations revealed by STAT prompt outrage

R1 RCM gets $5.8 billion buyout offer from private equity firm

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Alabama frozen embryo ruling has major implications for IVF clinics

Cigna wins case to block Amy Bricker's move to CVS

Curing rare childhood diseases will falter unless Congress steps up

Wikipedia

entertainment

knowledge

leisure time